Meeting
2019 ASCO Annual Meeting
Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.
Authors
Carlos Hernando Barcenas
The University of Texas MD Anderson Cancer Center, Houston, TX
Carlos Hernando Barcenas , Sara A. Hurvitz , Jack A. Di Palma , Ron Bose , Arlene Chan , Amy Jo Chien , Cindy Farrell , Daniel Hunt , Leanne McCulloch , Amy Kupic , Debu Tripathy , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02400476
Citation
J Clin Oncol 37, 2019 (suppl; abstr 548)
DOI
10.1200/JCO.2019.37.15_suppl.548
Abstract #
548
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.
First Author: Gavin M. Marx
Poster
2014 ASCO Annual Meeting
TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
First Author: Rachel A. Freedman
Poster
2019 ASCO Annual Meeting
Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
First Author: Naomi RM Schwartz
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen